Core Laboratories NV (CLB) Price Target Raised to $115.00 at Citigroup Inc.
Core Laboratories NV (NYSE:CLB) had its price objective raised by equities researchers at Citigroup Inc. from $110.00 to $115.00 in a research note issued on Tuesday. The firm presently has a “neutral” rating on the stock. Citigroup Inc.’s price objective would indicate a potential upside of 0.50% from the stock’s previous close.
Other equities research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Core Laboratories NV in a report on Thursday, June 30th. KLR Group reaffirmed a “buy” rating and set a $180.00 price target (up previously from $166.00) on shares of Core Laboratories NV in a report on Monday, June 13th. Zacks Investment Research raised Core Laboratories NV from a “hold” rating to a “buy” rating and set a $138.00 price target on the stock in a report on Wednesday, July 20th. DA Davidson started coverage on Core Laboratories NV in a report on Wednesday, October 5th. They set a “buy” rating and a $136.00 price target on the stock. Finally, Loop Capital initiated coverage on Core Laboratories NV in a report on Friday, September 30th. They set a “hold” rating and a $120.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. Core Laboratories NV has a consensus rating of “Hold” and a consensus target price of $121.61.
Core Laboratories NV (NYSE:CLB) traded down 0.38% during midday trading on Tuesday, reaching $114.00. The company had a trading volume of 179,282 shares. Core Laboratories NV has a 52-week low of $84.50 and a 52-week high of $135.49. The company’s 50 day moving average is $111.09 and its 200-day moving average is $117.57. The company has a market capitalization of $5.03 billion, a P/E ratio of 60.48 and a beta of 1.45.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/core-laboratories-nv-clb-price-target-raised-to-115-00-at-citigroup-inc.html
Core Laboratories NV (NYSE:CLB) last released its quarterly earnings results on Wednesday, July 20th. The company reported $0.35 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.35. The company had revenue of $148.10 million for the quarter, compared to analysts’ expectations of $146.37 million. Core Laboratories NV had a return on equity of 344.55% and a net margin of 11.81%. The business’s revenue for the quarter was down 27.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.81 earnings per share. Equities analysts expect that Core Laboratories NV will post $1.54 earnings per share for the current fiscal year.
Several large investors have recently modified their holdings of CLB. Virginia Retirement System bought a new stake in shares of Core Laboratories NV during the first quarter worth about $291,000. TIAA CREF Investment Management LLC raised its stake in shares of Core Laboratories NV by 2.5% in the first quarter. TIAA CREF Investment Management LLC now owns 36,509 shares of the company’s stock worth $4,104,000 after buying an additional 876 shares during the period. Franklin Resources Inc. raised its stake in shares of Core Laboratories NV by 0.3% in the first quarter. Franklin Resources Inc. now owns 600,100 shares of the company’s stock worth $67,457,000 after buying an additional 1,600 shares during the period. BlackRock Group LTD raised its stake in shares of Core Laboratories NV by 5.4% in the first quarter. BlackRock Group LTD now owns 280,960 shares of the company’s stock worth $31,582,000 after buying an additional 14,434 shares during the period. Finally, BlackRock Institutional Trust Company N.A. raised its stake in shares of Core Laboratories NV by 0.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 724,290 shares of the company’s stock worth $81,417,000 after buying an additional 3,461 shares during the period.
About Core Laboratories NV
Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.
Receive News & Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related companies with MarketBeat.com's FREE daily email newsletter.